Bipolar Disorders: Mixed States, Rapid-Cycling, and Atypical Forms

362 R. W. Baker et al.Table 16.1 Improvement from baseline Young Mania Rating Scale in psychotic versusnon-psychotic patients treated with olanzapine or a comparatorDuration Group Psychotic Non-psychotic Interaction3 weeks Olanzapine 34% (n ¼ 38) 39% (n ¼ 32) P ¼ 0.880Placebo 19% (n ¼ 33) 17% (n ¼ 33)3 weeks Olanzapine 44% (n ¼ 62) 54% (n ¼ 63) P ¼ 0.061Divalproex 41% (n ¼ 51) 34% (n ¼ 74)4 weeks Olanzapine 52% (n ¼ 33) 51% (n ¼ 21) P ¼ 0.110Placebo 13% (n ¼ 28) 44% (n ¼ 28)6 weeks Olanzapine þ lithium or valproate 54% (n ¼ 70) 62% (n ¼ 150) P ¼ 0.440Placebo þ lithium or valproate 45% (n ¼ 38) 39% (n ¼ 76)non-psychotic individuals, mania rating improvement was superior on olanzapine(54%) than on valproate (34%, P